NCT04695080

ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis

RecruitingPHASE2, PHASE3INTERVENTIONAL

Trial Details

Start: 2021-06-25Est. Completion: 2027-12-31

Enrollment target: 204 participants

Locations

Queens University Belfast (Belfast Health and Social Care Trust), Belfast, United Kingdom
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom
Cardiff University Hospital, Cardiff, United Kingdom
University Hospitals of Coventry and Warwickshire NHS Trust, Coventry, United Kingdom
Anne Rowling Clinic, University of Edinburgh, Edinburgh, United Kingdom
Queen Elizabeth University Hospital Glasgow, Glasgow, United Kingdom
University Hospital Hairmyres, NHS Lanarkshire, Glasgow, United Kingdom
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Walton Centre NHS Trust, Liverpool, United Kingdom
Royal London Hospital, London, United Kingdom
Royal Free London NHS Foundation Trust, London, United Kingdom
Queen's Hospital (Havering and Redbridge University Hospitals NHS Trust), London, United Kingdom
Lewisham and Greenwich NHS Trust, London, United Kingdom
St George's University Hospitals NHS Foundation Trust, London, United Kingdom
Luton and Dunstable Hospital, Luton, United Kingdom

MULTIPL SCLEROSİS

Multiple Sclerosis (MS) is a chronic neurological disease that can affect daily functioning, mobility, and overall quali…

Hatay, Turkey (Türkiye)Est. completion Dec 31, 2027

Multiple Sclerosis

Despite significant advancements in multiple sclerosis (MS) treatment over the past decade, a specific imaging biomarker…

Barcelona, SpainEst. completion Dec 1, 2029

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.